Amid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads.
Key Takeaways
-
While Zai Lab and others have built up massive reserves of in-licensed assets over the years, deals adding external molecules to boost pipelines have been thinning out since 2021.
Jump-started by frontrunner Zai Lab Ltd.’s successful introduction of GSK plc’s blockbuster cancer drug Zejula (niraparib) into China...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?